|

ALE.P03 Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 1/2: 1

Top Sponsors

  • Alentis Therapeutics AG1

Indications

  • Squamous Non-small-cell Lung Cancer1
  • Cervical Squamous Cell Carcinoma1
  • Urothelial Carcinoma1
  • Intrahepatic Cholangiocarcinoma1
  • Colorectal Cancer1

Phoenix, Arizona1 trial

A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors

Mayo Clinic Comprehensive Cancer Center

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.